Fig. 7

The selective HDAC3 inhibitor, RGFP966, alleviated BLM-induced pulmonary fibrosis and EMT in vivo. A Schematic diagram of RGFP966 intervention. Histological analyses using H&E staining, masson staining, PSR staining and Ashcroft score for fibrosis in saline-treated and BLM-treated mice at day 21 after RGFP966 was administered intraperitoneally. (× 200, n = 5). B Representative images of E-cadherin and vimentin immunofluorescence staining and quantitation in lung tissues from saline-treated and BLM-treated mice at day 21 after RGFP966 was administered intraperitoneally. (× 400, n = 5). C, D The relative mRNA and protein level of Col 1, α-SMA, E-cadherin, N-cadherin, vimentin and GATA3 in lung tissues from saline-treated and BLM-treated mice at day 21 after RGFP966 was administered intraperitoneally. (n = 5). (*P < 0.05, **P < 0.01, ***P < 0.001, ^nsP > 0.05)